DiaMedica Therapeutics (DMAC) Proxy Filing summary

Executive summary

• Annual General Meeting scheduled for May 15, 2025, at the company's Minneapolis headquarters.

• Shareholders are invited to vote on key proposals, including director elections, auditor appointment, and executive compensation.

Voting matters and shareholder proposals

• Election of seven directors to serve until the next Annual General Meeting or until successors are elected.

• Appointment of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2025, with board authorized to set remuneration.

• Advisory (non-binding) vote to approve executive compensation.

• Board recommends voting in favor of all proposals.

Board of directors and corporate governance

• Seven nominees listed for director positions: Michael Giuffre, Richard Kuntz, Tanya Lewis, Daniel O'Connor, James Parsons, Rick Pauls, and Charles Semba.